A list of medications routinely prescribed in primary care practice that should be used cautiously or avoided in patients with chronic kidney disease (CKD) was compiled in a recently published study in the Annals of Pharmacotherapy.
Chronic kidney disease (CKD) is a commonly diagnosed condition, affecting approximately 30 million adults in the United States.1 CKD refers to a diverse group of pathologies that result in kidney function decline for at least 3 months.2,3 Kidney disease etiologies are generally classified into 3 categories: prerenal, intrinsic renal, and postrenal. Prerenal disease is marked…
A study of patients with chronic kidney disease found that regular and occasional binge drinkers had double the risk of disease progression compared with non-drinkers.
Increasing levels of fibroblast growth factor 23 in patients with chronic kidney disease are independently associated with an increased risk of requiring maintenance dialysis or a kidney transplant, a study found.
Compared with never-drinkers, individuals who consumed 2 to 7, 8 to 14, and 15 or more drinks per week had significant 12%, 20%, 29%, and 23% decreased risks of incident chronic kidney disease, respectively, in adjusted analyses, according to a new report.
The FDA has accepted for review the New Drug Application (NDA) for veverimer (TRC101; Tricida) for the treatment of metabolic acidosis in patients with chronic kidney disease (CKD).
Potentially nephrotoxic meds prescribed at higher rate to children with versus without chronic kidney disease.
Risk equations had median C-values of 0.845 and 0.801 for cohorts with, without diabetes, respectively
Risk for hospitalization with encephalopathy higher for baclofen starting dose of ≥20 versus <20 mg/day
In a study, approximately one-fifth of CKD patients with metabolic acidosis received a diagnostic code for it.
